• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Monday, October 6, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Chemistry

The BrightFocus Foundation grants an Alzheimer’s Disease Research Standard Award to a CNIC project

Bioengineer by Bioengineer
May 24, 2022
in Chemistry
Reading Time: 3 mins read
0
Photo
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

The US nonprofit organization BrightFocus Foundation has granted an Alzheimer’s Disease Research Standard Award to the project ‘Understanding the impact of midlife cardiovascular risk factors & subclinical atherosclerosis on brain health: a role in Alzheimer´s disease’. The project is coordinated by Dr. Marta Cortés Canteli at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) together with CNIC General Director Dr. Valentín Fuster and Dr. Juan Domingo Gispert, of the CNIC and the Barcelonaβeta Brain Research Center.

Photo

Credit: CNIC

The US nonprofit organization BrightFocus Foundation has granted an Alzheimer’s Disease Research Standard Award to the project ‘Understanding the impact of midlife cardiovascular risk factors & subclinical atherosclerosis on brain health: a role in Alzheimer´s disease’. The project is coordinated by Dr. Marta Cortés Canteli at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) together with CNIC General Director Dr. Valentín Fuster and Dr. Juan Domingo Gispert, of the CNIC and the Barcelonaβeta Brain Research Center.

The project will receive annual funding of $100,000 over 3 years. Also participating in the project are CNIC scientists Dr. Borja Ibáñez and Dr. Fátima Sanchez Cabo and external partners Dr. Kaj Blennow and Dr. Henrik Zetterberg of the University of Gothenburg (Sweden), who are world leaders in the measurement of plasma biomarkers.

The project will examine longitudinal changes in plasma biomarkers of neuronal injury, neuroinflammation, and Alzheimer’s disease in participants in the PESA-CNIC-SANTANDER study who have undergone imaging studies to map brain metabolism (J Am Coll Cardiol 2021;77:888–98). The project will determine whether these biomarkers are linked to the presence of cardiovascular risk factors and subclinical cardiovascular disease, among other variables. In this way, aim is to determine if there is an association between cardiovascular and cerebral disease during their subclinical phases and to identify the mediators and possible causes of this association.

The Progression of Early Subclinical Atherosclerosis (PESA-CNIC-SANTANDER) study is a long-term prospective study that is now in its second decade. The study monitors the cardiovascular health of more than 4000 asymptomatic middle-aged individuals with the aim of determining the presence of subclinical atherosclerotic disease and associated disorders from the earliest stages through to the onset of the symptomatic phase.

Results from PESA published in various scientific journals show that subclinical atherosclerosis is frequent in this cohort of middle-aged, healthy individuals. Moreover, Dr. Cortes Canteli noted that the results show “that in PESA participants with subclinical atherosclerosis, cardiovascular risk and cardiovascular disease are associated with cerebral hypometabolism in brain regions that are also hypometabolic in Alzheimer’s disease.”

Dr. Cortes Canteli went on to say that now, with the funding from BrightFocus, “we will take this analysis further and determine if this cerebral hypometabolism is the result of a neuronal lesion and if it is associated with neuroinflammation and signs of Alzheimer’s disease.”

Dr. Cortes Canteli concluded that the new study “will mark an important advance toward the development of preventive interventions to reduce the incidence of Alzheimer dementia in old age.”

“We are so proud and excited to be funding Dr. Cortés Canteli ‘s project that will provide invaluable information about how cardiovascular risk contributes to cognitive decline and the onset of dementia,” said Sharyn Rossi, PhD, Director of Scientific Programs, Neuroscience at BrightFocus.

 



Share12Tweet8Share2ShareShareShare2

Related Posts

blank

Selective Arylating Uncommon C–F Bonds in Polyfluoroarenes

October 4, 2025
Building Larger Hydrocarbons for Optical Cycling

Building Larger Hydrocarbons for Optical Cycling

October 4, 2025

Scientists Discover How Enzymes “Dance” During Their Work—and Why It Matters

October 4, 2025

Electron Donor–Acceptor Complexes Enable Asymmetric Photocatalysis

October 4, 2025

POPULAR NEWS

  • New Study Reveals the Science Behind Exercise and Weight Loss

    New Study Reveals the Science Behind Exercise and Weight Loss

    95 shares
    Share 38 Tweet 24
  • New Study Indicates Children’s Risk of Long COVID Could Double Following a Second Infection – The Lancet Infectious Diseases

    93 shares
    Share 37 Tweet 23
  • New Insights Suggest ALS May Be an Autoimmune Disease

    71 shares
    Share 28 Tweet 18
  • Physicists Develop Visible Time Crystal for the First Time

    75 shares
    Share 30 Tweet 19

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

HUWE1 Loss Drives Stemness, Drug Resistance in CRC

Accounting for Albedo in Carbon Market Protocols

Designing Relationships in Intrinsically Disordered Proteins

Subscribe to Blog via Email

Success! An email was just sent to confirm your subscription. Please find the email now and click 'Confirm' to start subscribing.

Join 63 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.